The Sonata™ System (previously VizAblate®), developed by Gynesonics, is an incisionless, transcervical system that combines ultrasound image guidance with radiofrequency (RF) ablation. The system is designed to treat symptomatic uterine fibroids in a hospital outpatient setting, depending on anaesthetic requirements.
Relugolix is a small molecule that binds to the gonadotropin-releasing hormone receptor in the pituitary gland, decreasing the release of hormones which control oestrogen and progesterone production by the ovaries. Results from clinical trials demonstrated that relugolix in combination with estradiol and norethisterone acetate reduced menstrual bleeding in women with uterine fibroids. Relugolix is administered orally, and if licensed would offer an additional treatment option for women moderate to severe symptoms associated with uterine fibroids.